2024 VC fore­cast: Clin­i­cal-stage CD­MOs like­ly to have uptick in de­mand but spe­cial­iza­tion crit­i­cal

Clin­i­cal-stage CD­MOs should ex­pect a rise in de­mand in 2024 as fund­ing for ear­ly-stage bio­phar­ma sta­bi­lizes and biotechs may shed their in-house man­u­fac­tur­ing to save cash, ac­cord­ing to three VCs in­ter­viewed by End­points News.

“If you’re a biotech com­pa­ny and you don’t have to in­vest in your own man­u­fac­tur­ing in­fra­struc­ture, you are ac­tu­al­ly go­ing to be in that buck­et of com­pa­nies that is more like­ly to at­tract in­vest­ment,” Eclipse Ven­tures part­ner Justin But­ler added.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.